Literature DB >> 17179020

Atherosclerotic renovascular disease in older US patients starting dialysis, 1996 to 2001.

Haifeng Guo1, Philip A Kalra, David T Gilbertson, Jiannong Liu, Shu-Cheng Chen, Allan J Collins, Robert N Foley.   

Abstract

BACKGROUND: Temporal trends regarding the epidemiology of atherosclerotic renovascular disease (ARVD) in dialysis populations are poorly defined. METHODS AND
RESULTS: United States Renal Data System data were used to identify patients aged 67 years or older at dialysis inception between 1996 and 2001 (n=146,973). Medicare claims in the preceding 2 years were used to identify ARVD and revascularization procedures. Prior ARVD rose from 7.1% to 11.2% between 1996 and 2001 (adjusted odds ratio [AOR], 1.68). Other associations included hypertensive end-stage renal disease (ESRD; AOR, 2.21), ESRD network (AOR, 0.44 in network 17 versus 1.00 in network 1), peripheral vascular disease (AOR, 1.65), black race (AOR, 0.44), urologic cause of ESRD (AOR, 0.57), age >85 years (AOR, 0.58), substance dependency (AOR, 0.62), and inability to ambulate or transfer (AOR, 0.67). The proportion of ARVD patients undergoing revascularization rose from 14.6% to 16.7% between 1996 and 2001 (AOR, 1.27). Other associations included hypertension (AOR, 2.10), ESRD network (AOR, 2.07 for network 13 versus 1.00 in network 1), age >85 years (AOR, 0.53), and black race (AOR, 0.54). The rise in ARVD was not reflected in the proportion of patients with renovascular disease listed as cause of ESRD on the Medical Evidence Report at dialysis inception (5.5% in 1996, 5.0% in 2001).
CONCLUSIONS: ARVD diagnoses have become more common in older patients beginning dialysis therapy. The association of demographic factors including age, race, and geographic residence with utilization patterns suggests possible barriers to care.

Entities:  

Mesh:

Year:  2006        PMID: 17179020     DOI: 10.1161/CIRCULATIONAHA.106.637751

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Inflammatory cell markers as indicators of atherosclerotic renovascular disease.

Authors:  Stephen C Textor; Lilach O Lerman
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-12       Impact factor: 8.237

2.  Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates.

Authors:  Mira T Keddis; Vesna D Garovic; Kent R Bailey; Christina M Wood; Yassaman Raissian; Joseph P Grande
Journal:  Nephrol Dial Transplant       Date:  2010-05-25       Impact factor: 5.992

Review 3.  Atherosclerotic renal artery stenosis: current status.

Authors:  Soon Hyo Kwon; Lilach O Lerman
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

4.  Use of renin-angiotensin inhibitors in people with renal artery stenosis.

Authors:  Kaleigh L Evans; Katherine R Tuttle; David A Folt; Taylor Dawson; Steven T Haller; Pamela S Brewster; Wencan He; Kenneth Jamerson; Lance D Dworkin; Donald E Cutlip; Timothy P Murphy; Ralph B D'Agostino; William Henrich; Christopher J Cooper
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 8.237

Review 5.  Diagnosis and management of atherosclerotic renal artery stenosis: improving patient selection and outcomes.

Authors:  Christopher J White; Jeffrey W Olin
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

6.  TGF expression and macrophage accumulation in atherosclerotic renal artery stenosis.

Authors:  Monika L Gloviczki; Mira T Keddis; Vesna D Garovic; Hanna Friedman; Sandra Herrmann; Michael A McKusick; Sanjay Misra; Joseph P Grande; Lilach O Lerman; Stephen C Textor
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-20       Impact factor: 8.237

Review 7.  Endovascular versus medical therapy for atherosclerotic renovascular disease.

Authors:  Mark Shipeng Yu; David A Folt; Christopher A Drummond; Steven T Haller; Emily L Cooper; Pamela Brewster; Kaleigh L Evans; Christopher J Cooper
Journal:  Curr Atheroscler Rep       Date:  2014-12       Impact factor: 5.113

Review 8.  Revascularization as a treatment to improve renal function.

Authors:  Helen V Alderson; James P Ritchie; Philip A Kalra
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-02-20

9.  The importance of proteinuria and prior cardiovascular disease in all major clinical outcomes of atherosclerotic renovascular disease - a single-center observational study.

Authors:  Diana Vassallo; James Ritchie; Darren Green; Constantina Chrysochou; Joseph Blunt; Philip A Kalra
Journal:  BMC Nephrol       Date:  2016-12-07       Impact factor: 2.388

10.  Lipoprotein (a) as a residual risk factor for atherosclerotic renal artery stenosis in hypertensive patients: a hospital-based cross-sectional study.

Authors:  Xiangming Hu; Xing Yang; Xida Li; Demou Luo; Yingling Zhou; Haojian Dong
Journal:  Lipids Health Dis       Date:  2020-07-23       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.